Multi-Genotype HCV Vaccine E1E2 Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunogenic compositions fail to effectively induce an immune response against multiple hepatitis C virus (HCV) genotypes, particularly genotypes 1 and 3, which are prevalent worldwide, leading to chronic infections and liver-related complications.
Innovation Solution
Development of immunogenic compositions comprising HCV E1 and E2 polypeptides from two or more different genotypes, including genotype 1, 2, and 3, combined with a pharmaceutically acceptable excipient, such as adjuvants like MF59, alum, or CpG oligonucleotides, to stimulate an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If immunogenic compositions use polypeptides from a single HCV genotype, then the immune response is targeted and strong against that specific genotype, but the protection is limited and does not effectively cover multiple genotypes
Solution Approach 1:
The patent combines E1 and E2 polypeptides from multiple different HCV genotypes into a single immunogenic composition. This merging of diverse polypeptide sources enables the vaccine to induce immune responses against multiple genotypes simultaneously, resolving the contradiction between targeted effectiveness and broad coverage.
Solution Approach 2:
The immunogenic composition is designed to perform multiple functions by incorporating polypeptides from different genotypes, making it universally effective against various HCV strains. This multi-functionality allows a single vaccine formulation to provide protection across multiple genotype groups, addressing the adaptability requirement.
2Adaptability or versatility
If immunogenic compositions include polypeptides from multiple HCV genotypes, then the breadth of protection increases, but the complexity of the composition and immune response induction becomes more challenging
Solution Approach 1:
The patent segments the HCV envelope protein into distinct E1 and E2 polypeptide components from different genotypes. This segmentation allows for systematic combination of multiple genotypes while maintaining clear structural and functional definitions, simplifying the complexity management.
Solution Approach 2:
The immunogenic composition uses composite materials by combining polypeptides from multiple HCV genotypes into a unified formulation. This composite approach integrates diverse biological materials while maintaining a consistent structural framework, managing complexity through organized integration.
3Reliability
If the immunogenic composition uses E1 and E2 polypeptides from multiple genotypes, then cross-neutralization capability improves, but the manufacturing and formulation process becomes more complex
Solution Approach 1:
The patent employs partial action by incorporating only the essential E1 and E2 polypeptide regions from multiple genotypes rather than entire viral proteins or genomes. This partial approach achieves sufficient cross-neutralization capability while significantly reducing manufacturing complexity compared to using complete viral components.
Data Source
AI summary
The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.